Overview

Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)

Status:
Completed
Trial end date:
2017-12-15
Target enrollment:
Participant gender:
Summary
Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Collaborator:
Orion Corporation, Orion Pharma